FilingReader Intelligence

Taiho Pharmaceutical to acquire Araris Biotech for $400m

March 17, 2025 at 12:00 PM UTCBy FilingReader AI

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, will acquire Araris Biotech for $400 million upfront, with potential milestone payments reaching up to $740 million. The acquisition, expected to close in the first half of 2025, will bolster Taiho's biologics research and development capabilities. Araris, founded in 2019, focuses on ADC technology, which selectively delivers cytotoxic drugs to cancer cells. Taiho plans to leverage Araris' AraLinQ™ ADC linker platform to expand its oncology portfolio, complementing its existing expertise in small-molecule drugs. The acquisition is expected to enhance Taiho's drug discovery capabilities, combining small molecules and ADCs, for continued expansion of its oncology portfolio.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

TSE:4578Tokyo Stock Exchange

News Alerts

Get instant email alerts when Otsuka Holdings publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →